Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

References

• Baumeister, D., G. Barnes, G. Giaroli, and D. Tracy. 2014. Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Therapeutic Advances in Psychopharmacology 4 (4):156–69. doi:10.1177/2045125314527985.
   PubMedGoogle Scholar
• Berman, M. G., S. Peltier, D. E. Nee, E. Kross, P. J. Deldin, and J. Jonides. 2010. Depression, rumination and the default network. Social Cognitive and Affective Neuroscience 6 (5):548–55.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., M. Bolstridge, J. Rucker, C. M. Day, D. Erritzoe, M. Kaelen, M. Bloomfield, J. A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V. H. Curran, and D. J. Nutt. 2016. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry 3 (7):619–27. doi:10.1016/S2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., D. Erritzoe, T. Williams, J. M. Stone, L. J. Reed, A. Colasanti, R. J. Tyacke, R. Leech, A. L. Malizia, K. Murphy, P. Hobden, J. Evans, A. Feilding, R. G. Wise, and D. J. Nutt. 2012. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences U S A 109 (6):2138–43. doi:10.1073/pnas.1119598109.
   PubMed Web of Science ®Google Scholar
• Cuthbert, B. N. 2015. Research domain criteria: Toward future psychiatric nosologies. Dialogues in Clinical Neuroscience 17 (1):89–97.
   PubMed Web of Science ®Google Scholar
• Greicius, M. D., B. H. Flores, V. Menon, G. H. Glover, H. B. Solvason, H. Kenna, A. L. Reiss, and A. F. Schatzberg. 2007. Resting-state functional connectivity in major depression: Abnormally increased contributions from subgenual cingulate cortex and thalamus. Biological Psychiatry 62 (5):429–37. doi:10.1016/j.biopsych.2006.09.020.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology 30 (12):1181–97. doi:10.1177/0269881116675513.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Grob, C. S., A. L. Danforth, G. S. Chopra, M. Hagerty, C. R. McKay, A. L. Halberstadt, and G. R. Greer. 2011. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry 68 (1):71–78. doi:10.1001/archgenpsychiatry.2010.116.
   PubMed Web of Science ®Google Scholar
• Hasler, F., D. Bourquin, R. Brenneisen, T. Bär, and F. X. Vollenweider. 1997. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae 72 (3):175–84. doi:10.1016/S0031-6865(97)00014-9.
   PubMedGoogle Scholar
• Hasler, F., D. Bourquin, R. Brenneisen, and F. X. Vollenweider. 2002. Renal excretion profiles of psilocin following oral administration of psilocybin: A controlled study in man. Journal of Pharmaceutical and Biomedical Analysis 30 (2):331–39. doi:10.1016/S0731-7085(02)00278-9.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, M. P. Cosimano, and R. R. Griffiths. 2014. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology 28 (11):983–92. doi:10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2016. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60.
   PubMed Web of Science ®Google Scholar
• Kometer, M., A. Schmidt, R. Bachmann, E. Studerus, E. Seifritz, and F. X. Vollenweider. 2012. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry 72 (11):898–906. doi:10.1016/j.biopsych.2012.04.005.
   PubMed Web of Science ®Google Scholar
• Lebedev, A. V., M. Lövdén, G. Rosenthal, A. Feilding, D. J. Nutt, and R. L. Carhart‐Harris. 2015. Finding the self by losing the self: Neural correlates of ego‐dissolution under psilocybin. Human Brain Mapping 36 (8):3137–53. doi:10.1002/hbm.v36.8.
   PubMed Web of Science ®Google Scholar
• Lindenblatt, H., E. Krämer, P. Holzmann-Erens, E. Gouzoulis-Mayfrank, and K. A. Kovar. 1998. Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: Comparison of liquid-liquid extraction with automated on-line solid-phase extraction. Journal of Chromatography B: Biomedical Sciences and Applications 709 (2):255–63. doi:10.1016/S0378-4347(98)00067-X.
   PubMed Web of Science ®Google Scholar
• Manevski, N., M. Kurkela, C. Höglund, T. Mauriala, M. H. Court, J. Yli-Kauhaluoma, and M. Finel. 2010. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metabolism and Disposition 38 (3):386–95. doi:10.1124/dmd.109.031138.
   PubMed Web of Science ®Google Scholar
• McKenna, D. J., D. B. Repke, L. Lo, and S. J. Peroutka. 1990. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology 29 (3):193–98. doi:10.1016/0028-3908(90)90001-8.
   PubMed Web of Science ®Google Scholar
• Menon, V. 2011. Large-scale brain networks and psychopathology: A unifying triple network model. Trends in Cognitive Sciences 15 (10):483–506.
   PubMed Web of Science ®Google Scholar
• Moreno, F. A., C. B. Wiegand, E. K. Taitano, and P. L. Delgado. 2006. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 67 (11):1735–40. doi:10.4088/JCP.v67n1110.
   PubMed Web of Science ®Google Scholar
• Muthukumaraswamy, S. D., R. L. Carhart-Harris, R. J. Moran, M. J. Brookes, T. M. Williams, D. Errtizoe, B. Sessa, A. Papadopoulos, M. Bolstridge, K. D. Singh, A. Feilding, K. J. Friston, and D. J. Nutt. 2013. Broadband cortical desynchronization underlies the human psychedelic state. The Journal of Neuroscience 33 (38):15171–83. doi:10.1523/JNEUROSCI.2063-13.2013.
   PubMed Web of Science ®Google Scholar
• Nagatomo, T., M. Rashid, H. A. Muntasir, and T. Komiyama. 2004. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacology and Therapeutics 104 (1):59–81. doi:10.1016/j.pharmthera.2004.08.005.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. 2004. Hallucinogens. Pharmacology and Therapeutics 101 (2):131–81. doi:10.1016/j.pharmthera.2003.11.002.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. 2016. Psychedelics. Pharmacological Reviews 68 (2):264–355. doi:10.1124/pr.115.011478.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E., M. W. Johnson, and C. D. Nichols. 2017. Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology & Therapeutics 101 (2):209–19.
   PubMed Web of Science ®Google Scholar
• Passie, T., J. Seifert, U. Schneider, and H. M. Emrich. 2002. The pharmacology of psilocybin. Addictition Biology 7 (4):357–64. doi:10.1080/1355621021000005937.
   PubMed Web of Science ®Google Scholar
• Pazos, A., A. Probst, and J. M. Palacios. 1987. Serotonin receptors in the human brain–III: Autoradiographic mapping of serotonin-1 receptors. Neuroscience 21 (1):97–122. doi:10.1016/0306-4522(87)90326-5.
   PubMed Web of Science ®Google Scholar
• Quednow, B. B., M. Kometer, M. A. Geyer, and F. X. Vollenweider. 2012. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37 (3):630–40. doi:10.1038/npp.2011.228.
   PubMed Web of Science ®Google Scholar
• Roseman, L., R. Leech, A. Feilding, D. J. Nutt, and R. L. Carhart-Harris. 2014. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience 8:204. doi:10.3389/fnhum.2014.00204.
   PubMed Web of Science ®Google Scholar
• Ross, S., A. Bossis, J. Guss, G. Agin-Liebes, T. Malone, B. Cohen, S. E. Mennenga, A. Belser, K. Kalliontzi, J. Babb, Z. Su, P. Corby, and B. L. Schmidt. 2016. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology 30 (12):1165–80. doi:10.1177/0269881116675512.
   PubMed Web of Science ®Google Scholar
• Tylš, F., T. Páleníček, and J. Horáček. 2014. Psilocybin: Summary of knowledge and new perspectives. European Neuropsychopharmacology 24 (3):342–56. doi:10.1016/j.euroneuro.2013.12.006.
   PubMed Web of Science ®Google Scholar
• Yu, A. M. 2008. Indolealkylamines: Biotransformations and potential drug-drug interactions. The AAPS Journal 10 (2):242–53. doi:10.1208/s12248-008-9028-5.
   PubMed Web of Science ®Google Scholar